Lynparza

Active substance

Olaparib

Holder

Clinigen on behalf of AstraZeneca

Status

Closed

Indication

Treatment of patients with deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation and who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting for TNBC or HER2-/ HR+ breast cancer unsuitable for further anti-hormonal therapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update